Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, represents the frontier of this drug class
Glucagon-like Peptide-1 7-36: A Physiological Incretin in Man
Needle design: Sharp, triple-bevel stainless-steel needle for smooth insertion, with an ultrafine (thin-wall) design to allow easier flow of insulin
doi: 10.1093/ajcn/88.2.263 128 VigniniABorroniFSabbatinelliJPugnaloniSAliaSTausMet al
doi: 10.3389/fendo.2024.1528457 Received 14 November 2024 Accepted 30 December 2024 Published 21 January 2025 Volume 15 - 2024 Edited by Claire Joanne Stocker, Aston University, United Kingdom Reviewed by Wael Sidrak, Abou Seifein Diabetes & Endocrine Center, Egypt Frederic Illouz, CHU Angers, France Christine Trapp, Connecticut Childrens Medical Center, United States Updates Copyright 2025 Koceva, Mleku Kozamernik, Jane, Herman, Ferjan and Jensterle